|
| A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
|
Pharmacological Action Bone Density Conservation Agents | Other names Sodium, Alendronate; MK217; MK 217; Bisphosphonate, Aminohydroxybutane; 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate; MK-217; Fosamax; Aminohydroxybutane Bisphosphonate; Alendronate Sodium; Alendronate Monosodium Salt, Trihydrate; 4-Amino-1-Hydroxybutylidene 1,1-BiphosphonateDrugs* :
ALENDRONATE;
ALENDRONATE SODIUM;
FOSAMAX;
FOSAMAX PLUS D
| |
| Substance | CAS Registry & name | Categories | Source | Drugs*
|
| technetium Tc 99m alendronate
| 0
|
*Organotechnetium Compounds Alendronate/*analogs & derivatives.
|
Nucl Med Biol 1997 Jan;24(1):27-33
|
prolyl-phenylalanyl-alendronate
| 0
|
*Dipeptides Alendronate/*analogs & derivatives.
|
J Med Chem 2000 Oct 5;43(20):3641-52
|
N-myristoylalendronic acid
| 0
|
Alendronate/*analogs & derivatives.
|
J Med Chem 2006 Jun 1;49(11):3060-3
| | |
| |
| | |